RTTNews | Apr 16, 2021 01:53AM EDT

01:52 Friday, April 16, 2021 (RTTNews.com) - Bausch Health Companies Inc. (BHC), Bausch + Lomb, and Nicox announced VYZULTA, 0.024%, has received regulatory approval from the Brazilian Health Regulatory Agency. It is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The approval of VYZULTA in Brazil marks its tenth regulatory approval.

VYZULTA, or latanoprostene bunod ophthalmic solution, is now approved in 10 markets, including Argentina, Brazil, Canada, Colombia, Hong Kong, Mexico, South Korea, Taiwan, Ukraine and the United States. Nicox generates revenue from VYZULTA in glaucoma, licensed exclusively worldwide to Bausch + Lomb.

Read the original article on RTTNews ( https://www.rttnews.com/3185471/bausch-announces-approval-of-vyzulta-in-brazil-quick-facts.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved